Amphastar Pharmaceuticals, Inc. (AMPH)
- Previous Close
38.65 - Open
38.52 - Bid 39.85 x 100
- Ask 39.98 x 100
- Day's Range
38.48 - 39.91 - 52 Week Range
35.62 - 67.66 - Volume
242,459 - Avg. Volume
436,891 - Market Cap (intraday)
1.949B - Beta (5Y Monthly) 0.84
- PE Ratio (TTM)
15.34 - EPS (TTM)
2.60 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
63.25
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
www.amphastar.com1,761
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AMPH
Performance Overview: AMPH
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMPH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMPH
Valuation Measures
Market Cap
1.89B
Enterprise Value
2.25B
Trailing P/E
14.86
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.18
Price/Book (mrq)
2.95
Enterprise Value/Revenue
3.50
Enterprise Value/EBITDA
9.38
Financial Highlights
Profitability and Income Statement
Profit Margin
21.34%
Return on Assets (ttm)
11.07%
Return on Equity (ttm)
23.55%
Revenue (ttm)
644.4M
Net Income Avi to Common (ttm)
137.54M
Diluted EPS (ttm)
2.60
Balance Sheet and Cash Flow
Total Cash (mrq)
256.81M
Total Debt/Equity (mrq)
97.53%
Levered Free Cash Flow (ttm)
245.1M
Research Analysis: AMPH
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: AMPH
AMPH: What does Argus have to say about AMPH?
AMPHASTAR PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $43.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingNeutralPrice TargetAMPH: Lowering target price to $43.00
AMPHASTAR PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $43.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingNeutralPrice TargetAMPH: Lowering target price to $44.00
AMPHASTAR PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $44.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingNeutralPrice TargetAMPH: Lowering target price to $45.00
AMPHASTAR PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $45.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingNeutralPrice Target